Many treatments are now extending lives, but the measure of progress should not end with a scan or a survival curveTwo decades ago, a dear friend called me in a trembling voice. Was there hope for his young nephew, whose cancer had spread to the brain? Sadly, “no”, I said. But today, for such patients, there are options that were unimaginable back then.Recently, researchers at the European Society For Medical Oncology presented the latest chapter results from a randomised controlled trial of a bespoke cancer vaccine for patients with high-risk melanoma. The trial involved 1,137 patients whose melanoma had been surgically removed but remained at high recurrence risk. They received either pembrolizumab, an established immunotherapy, or pembrolizumab combined with an experimental mRNA vaccine, designed to help the immune system recognise and attack targets unique to the patient’s tumour. Continue reading...
As cancer treatments become more effective, we must ask: what is life like for the people who receive them? | Ranjana Srivastava
TH
The Guardian - UKBy Ranjana Srivastava
EXECUTIVE SUMMARY
Many treatments are now extending lives, but the measure of progress should not end with a scan or a survival curve Two decades ago, a dear friend called me in a trembling voice. Was there hope for his young nephew, whose cancer had spread to the brain? Sadly, “no”, I said. But today, for such patients, there are options that were unimaginable back then. Recently, researchers at the European Society For Medical Oncology presented the latest chapter results from a randomised controlled trial of a
Key Takeaways
- As cancer treatments become more effective, we must ask: what is life like for the people who receive them?
- | Ranjana Srivastava.
- Many treatments are now extending lives, but the measure of progress should not end with a scan or a survival curve Two decades ago, a dear friend called me in a trembling voice.
Read Complete Original Article
Published originally on The Guardian - UK
